FDA Reconsiders Leucovorin Labeling Amid RFK Jr.’s Autism Claims
The U.S. Food and Drug Administration (FDA) has distanced itself from former presidential candidate Robert F. Kennedy Jr.’s assertions that leuc…
Leucovorin, a form of folic acid commonly used to treat folate deficiency, has been the subject of controversy after RFK Jr. promoted it as a potential treatment for autism in 2022. The FDA’s initial statement suggested the agency was considering adding autism-related indications to the drug’s labeling, though no formal approval was granted. Recent clarification from the agency indicates it is retracting that position, emphasizing the need for rigorous scientific validation before altering drug labels.
Healthcare experts warn that prematurely endorsing unproven treatments for autism could lead to misinformation and divert resources from evidence-based therapies. Autism advocacy groups remain divided, with some praising the FDA’s cautious approach while others criticize the agency for undermining parental hope. The situation highlights the complex interplay between regulatory oversight, public health advocacy, and the pressures of medical innovation.